Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
September 26, 2024 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
September 26, 2024 15:17 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 23,954 restricted stock units and 13,915 warrants to employees...
Hagar hf.: Ákvörðun um að hefja formlegt söluferli á eignarhlutum Olís og Festi í Olíudreifingu ehf.
September 26, 2024 13:00 ET
|
Hagar hf.
Í tilkynningu Haga frá 10. apríl 2024 var meðal annars greint frá því að Olís, dótturfélag Haga, og Festi hefðu komist að samkomulagi um að hefja undirbúning sölumeðferðar á eignarhlutum félaganna í...
Festi hf.: Ákvörðun um að hefja formlegt söluferli á eignarhlutum Festi og Olís í Olíudreifingu ehf.
September 26, 2024 13:00 ET
|
Festi hf.
Í tilkynningu Festi, dags. 10. apríl 2024, var m.a. frá því greint að félagið og Olís, dótturfélag Haga, hefðu komist að samkomulagi um að hefja undirbúning sölumeðferðar á eignarhlutum félaganna í...
Festi hf.: Decision to initiate a formal sale process of Festi and Olís' shares in Olíudreifing ehf.
September 26, 2024 13:00 ET
|
Festi hf.
In Festi's announcement, dated 10 April 2024, it was announced that the company and Olís, a subsidiary of Hagar, had reached an agreement to begin preparations for the sale of the companies' shares in...
Félagsbústaðir hf. - Fjárhagsáætlun 2025
September 26, 2024 12:38 ET
|
Félagsbústaðir hf.
Stjórn Félagsbústaða hf. samþykkti á fundi sínum 26. september 2024 fjárhagsáætlun félagsins fyrir árið 2025 og langtímaáætlun fyrir árin 2026 til 2029. Fjárhagsáætlunin byggir á útgönguspá fyrir árið...
Bavarian Nordic opjusterer sine økonomiske forventninger til 2024
September 26, 2024 10:30 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 26. september 2024 – Bavarian Nordic A/S (OMX: BAVA) opjusterer sine økonomiske forventninger til 2024. På baggrund af den i dag offentliggjorte ordre på selskabets mpox-vaccine...
Bavarian Nordic Upgrades its Financial Guidance for 2024
September 26, 2024 10:30 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024. Based on today’s announced mpox vaccine order and additional orders secured,...
Bavarian Nordic indgår aftale med UNICEF om levering af 1 million doser mpox-vaccine
September 26, 2024 10:30 ET
|
Bavarian Nordic A/S
Første tildeling under UNICEF’s nødudbud, der skal sikre tilgængelighed af mpox-vacciner til Afrika KØBENHAVN, Danmark, 26. september 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag...
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
September 26, 2024 10:30 ET
|
Bavarian Nordic A/S
First award under UNICEF emergency tender to secure availability of mpox vaccines for Africa COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement...